Pepper Bio has acquired rights to the G1 Therapeutics drug, lerociclib, which shows promise for the treatment of liver cancer. The deal does not cover radioprotective applications. Lerociclib is designed to block cancer-driving proteins CDK and CD6. G1 previously generated positive clinical data for the drug in breast cancer but decided against further development. Pepper Bio’s technology identified CDK4/6 as important targets for treating liver cancer.
Why powerful, secure networks are critical for first-class healthcare
Healthcare systems are facing significant challenges including staff shortages, cybersecurity threats, and budget constraints, according to a report by the Healthcare Information and Management Systems
